Index of Issues: January, 1–62; February, 63–126; March, 127–182; April, 183–242; May, 243–304; July, 305–362; August, 363–424; September, 425–490; October, 491–550; November, 551–660.

INDEX OF AUTHORS

A

Adams AL, 617
Ad Hoc STD/HIV Transmission Group, 411
Adolescent Medicine HIV/AIDS Research Network, 296
Alary M, 401
Alessi E, 226
Al-Tawfiq JA, 111
Alter HJ, 178
Anderson RM, 636
Andreoni M, 159
Aral SO, 193, 215, 327, 343, 556
Arella M, 79
Asamoah-Adu A, 401
Asamoah-Adu C, 401
Ashley RL, 266

B

Bailey SBC, 168
Bakary DK, 159
Ballard R, 1, 21
Barlow R, 230
Becker MP, 617
Beck-Sague CM, 21
Bekoe V, 401
Bennett A, 320
Bergeron J, 79
Berman SM, 201
Blocker ME, 53
Boeke AJP, 504
Boily M-C, 558
Bolan G, 393, 446, 539
Boshoff C, 468
Bourboulia D, 468
Bouter LM, 504
Bowden FJ, 133, 588
Brody S, 60, 644
Bromberg K, 289
Brown JE, 183
Brown RC, 183
Bruckers L, 1
Buchacz K, 393
Bugarini R, 159
Bull SS, 545
Bwayo J, 417

C

Calderon M, 386
Caprilli F, 87
Celentano D, 127
Celum C, 193
Chandeying V, 358
Chan RKW, 39, 208
Chen CY, 21
Chen S, 133
Chen X-S, 138
Chick SE, 617
Ciemins EL, 165, 249
Claeys P, 417
Clark RA, 284
Cohen DA, 305, 473
Cohen MS, 143
Coles FB, 508
Collandre H, 468
Conley J, 1
Connor S, 193
Corey L, 30
Coronado N, 193
Crescimbeni E, 87
Cusan M, 292
Cusini M, 226, 292

D

Dallabetta G, 1
Dangor Y, 21
d'Arcy H, 230
Deal CD, 278
Debiao W, 480
Deceuninck G, 401
Decleva I, 226, 292
DeCoito T, 1
DeHovitz J, 338
Deslandes S, 401
Devillé W, 504
Di Carlo A, 87
DiClemente RJ, 175
Dietze R, 468
Dillner J, 425
Djajakusumah TS, 152
Doherty-Iddings P, 119
Douglas JM, 411
Douglas JM Jr, 236, 446
Dubois M-J, 458
Durako SJ, 296

E

Eagleton M, 266
Ehrhardt A, 127
El-Bassel N, 93
Ensoli B, 159

F

Fakile Y, 46
Fariley CK, 133
Farley TA, 188, 305
Farmer M, 313
Faxelid E, 496
Fehler G, 1, 21
Feldman JG, 338
Ferguson NM, 600
Feudo R, 119
Finelli L, 201
Finlinson HA, 119
Fishbein M, 101, 127, 201, 452
Fitzgerald S, 343
Fleming DT, 68
Flood J, 165, 249
Fonck K, 417
Fortenberry JD, 49
Foster M, 236
Foster SE, 119
Fourie HJ, 353
Fox K, 143, 530
Foxman B, 230
Franco E, 79
French P, 431
Frost EH, 401

G

Galea J, 193
Gambini D, 226
Garland SM, 133, 358
Garnett G, 127, 201, 579, 588, 600, 636
Gaydos C, 313
Ghani AC, 579
Ghislanzoni M, 226
Gilbert L, 93
Gillespie B, 230
Gilman RH, 386
Gilmour E, 353
Giouzeppos O, 133
Giuliani M, 87
Glikoutou M, 159
Goedert JJ, 178
Golden MR, 329
Gollub E, 431
Gong X-D, 138
Gorbach PM, 193, 320
Graham NMH, 252, 313
Greenberg A, 508
Grésenguet G, 458
Gunn RA, 343
Guoming L, 115

H

Hadjivassiliou M, 259
Hakama M, 425
Hammerschlag M, 289
Hammett TM, 119
Harezlak J, 111
Harmon P, 119
Hayes M, 146
Heath B, 12
Henderson GE, 143
Hernandez M, 393, 539
Hillier SL, 74
Hoffman IF, 530
Holland CA, 296
Holmes KK, 9, 193, 215, 320
Holtgrave D, 127
Homel P, 289
Hook III EW, 175
Htun Y, 21
Huang J, 168
Hughes JP, 215

J

Jaccard J, 127
Jacobson DL, 252, 313
Jager JC, 518
Jarvis B, 452
Jeter G, 119
Jinlan Y, 480
Joanis CL, 119
Johnson D, 12
Johnson G, 188, 305
Jones CA, 146
Jones JL, 483
Joyner JL, 236
Judson FN, 236

K

Kahn RH, 188, 305
Kamb ML, 446
Karim SSA, 353
Kassie A, 284
Kassler WJ, 32
Katz BP, 111
Katz MH, 393
Keller R, 468
Kent CK, 165, 249
Khonde N, 401
Kibur M, 425
Kidula N, 417
Kimbrough L, 12
Kirui P, 417
Kissinger P, 284
Klausner JD, 165, 249, 393, 539
Knapp JS, 46
Knaup RC, 146
Koh D, 39, 208
Koopman JS, 617
Kopicko JJ, 284
Koplan J, 63
Koskela P, 425
Krantz I, 496
Kretzschmar M, 518, 627
Krieger JN, 241
Krüger Kjaer S, 438
Kuder JM, 363
Kwan M, 278
Kyriakis KP, 259

L

Landesman S, 338
Lansky A, 483
Latka M, 431
Lehtinen M, 425
Leidl R, 518
Leinikki P, 425
Leng HB, 320
Leone PA, 530
Lepri AC, 87
Levine WC, 53, 68, 201
Levin L, 296
Lewis-Hardy R, 12
Liang G-J, 138
Lin LS, 446
Lupica L, 226

M

Maini A, 87
Malotte CK, 446
Markowitz L, 329
Mason TH, 119
Mâsse B, 558
Matsumoto A, 178
Ma Y, 296
Mayer KH, 119
Mays RM, 49
Mberyo-Yaah, 458
McCormack WM, 554
McFarland W, 393, 539
McFarlane M, 545
McPherson JT, 530
Meheus A, 152
Mehta SD, 154
Meijer CJLM, 438, 504
Mengoli C, 292
Mertz KJ, 201
Miller JN, 551
Miller WC, 530
Mills J, 270
Mills S, 320
Minchang W, 480
Minkoff H, 338
Miranda AE, 491

Index of Issues: January, 1–62; February, 63–126; March, 127–182; April, 183–242; May, 243–304; July, 305–362; August, 363–424; September, 425–490; October, 491–550; November, 551–660.

INDEX OF AUTHORS

A

Adams AL, 617
Ad Hoc STD/HIV Transmission Group, 411
Adolescent Medicine HIV/AIDS Research Network, 296
Alary M, 401
Alessi E, 226
Al-Tawfiq JA, 111
Alter HJ, 178
Anderson RM, 636
Andreoni M, 159
Aral SO, 193, 215, 327, 343, 556
Arella M, 79
Asamoah-Adu A, 401
Asamoah-Adu C, 401
Ashley RL, 266

B

Bailey SBC, 168
Bakary DK, 159
Ballard R, 1, 21
Barlow R, 230
Becker MP, 617
Beck-Sague CM, 21
Bekoe V, 401
Bennett A, 320
Bergeron J, 79
Berman SM, 201
Blocker ME, 53
Boeke AJP, 504
Boily M-C, 558
Bolan G, 393, 446, 539
Boshoff C, 468
Bourboulia D, 468
Bouter LM, 504
Bowden FJ, 133, 588
Brody S, 60, 644
Bromberg K, 289
Brown JE, 183
Brown RC, 183
Bruckers L, 1
Buchacz K, 393
Bugarini R, 159
Bull SS, 545
Bwayo J, 417

C

Calderon M, 386
Caprilli F, 87
Celentano D, 127
Celum C, 193
Chandeying V, 358
Chan RKW, 39, 208
Chen CY, 21
Chen S, 133
Chen X-S, 138
Chick SE, 617
Ciemins EL, 165, 249
Claeys P, 417
Clark RA, 284
Cohen DA, 305, 473
Cohen MS, 143
Coles FB, 508
Collandre H, 468
Conley J, 1
Connor S, 193
Corey L, 30
Coronado N, 193
Crescimbeni E, 87
Cusan M, 292
Cusini M, 226, 292

D

Dallabetta G, 1
Dangor Y, 21
d'Arcy H, 230
Deal CD, 278
Debiao W, 480
Deceuninck G, 401
Decleva I, 226, 292
DeCoito T, 1
DeHovitz J, 338
Deslandes S, 401
Devillé W, 504
Di Carlo A, 87
DiClemente RJ, 175
Dietze R, 468
Dillner J, 425
Djajakusumah TS, 152
Doherty-Iddings P, 119
Douglas JM, 411
Douglas JM Jr, 236, 446
Dubois M-J, 458
Durako SJ, 296

E

Eagleton M, 266
Ehrhardt A, 127
El-Bassel N, 93
Ensoli B, 159

F

Fakile Y, 46
Fariley CK, 133
Farley TA, 188, 305
Farmer M, 313
Faxelid E, 496
Fehler G, 1, 21
Feldman JG, 338
Ferguson NM, 600
Feudo R, 119
Finelli L, 201
Finlinson HA, 119
Fishbein M, 101, 127, 201, 452
Fitzgerald S, 343
Fleming DT, 68
Flood J, 165, 249
Fonck K, 417
Fortenberry JD, 49
Foster M, 236
Foster SE, 119
Fourie HJ, 353
Fox K, 143, 530
Foxman B, 230
Franco E, 79
French P, 431
Frost EH, 401

G

Galea J, 193
Gambini D, 226
Garland SM, 133, 358
Garnett G, 127, 201, 579, 588, 600, 636
Gaydos C, 313
Ghani AC, 579
Ghislanzoni M, 226
Gilbert L, 93
Gillespie B, 230
Gilman RH, 386
Gilmour E, 353
Giouzeppos O, 133
Giuliani M, 87
Glikoutou M, 159
Goedert JJ, 178
Golden MR, 329
Gollub E, 431
Gong X-D, 138
Gorbach PM, 193, 320
Graham NMH, 252, 313
Greenberg A, 508
Grésenguet G, 458
Gunn RA, 343
Guoming L, 115

H

Hadjivassiliou M, 259
Hakama M, 425
Hammerschlag M, 289
Hammett TM, 119
Harezlak J, 111
Harmon P, 119
Hayes M, 146
Heath B, 12
Henderson GE, 143
Hernandez M, 393, 539
Hillier SL, 74
Hoffman IF, 530
Holland CA, 296
Holmes KK, 9, 193, 215, 320
Holtgrave D, 127
Homel P, 289
Hook III EW, 175
Htun Y, 21
Huang J, 168
Hughes JP, 215

J

Jaccard J, 127
Jacobson DL, 252, 313
Jager JC, 518
Jarvis B, 452
Jeter G, 119
Jinlan Y, 480
Joanis CL, 119
Johnson D, 12
Johnson G, 188, 305
Jones CA, 146
Jones JL, 483
Joyner JL, 236
Judson FN, 236

K

Kahn RH, 188, 305
Kamb ML, 446
Karim SSA, 353
Kassie A, 284
Kassler WJ, 32
Katz BP, 111
Katz MH, 393
Keller R, 468
Kent CK, 165, 249
Khonde N, 401
Kibur M, 425
Kidula N, 417
Kimbrough L, 12
Kirui P, 417
Kissinger P, 284
Klausner JD, 165, 249, 393, 539
Knapp JS, 46
Knaup RC, 146
Koh D, 39, 208
Koopman JS, 617
Kopicko JJ, 284
Koplan J, 63
Koskela P, 425
Krantz I, 496
Kretzschmar M, 518, 627
Krieger JN, 241
Krüger Kjaer S, 438
Kuder JM, 363
Kwan M, 278
Kyriakis KP, 259

L

Landesman S, 338
Lansky A, 483
Latka M, 431
Lehtinen M, 425
Leidl R, 518
Leinikki P, 425
Leng HB, 320
Leone PA, 530
Lepri AC, 87
Levine WC, 53, 68, 201
Levin L, 296
Lewis-Hardy R, 12
Liang G-J, 138
Lin LS, 446
Lupica L, 226

M

Maini A, 87
Malotte CK, 446
Markowitz L, 329
Mason TH, 119
Mâsse B, 558
Matsumoto A, 178
Ma Y, 296
Mayer KH, 119
Mays RM, 49
Mberyo-Yaah, 458
McCormack WM, 554
McFarland W, 393, 539
McFarlane M, 545
McPherson JT, 530
Meheus A, 152
Mehta SD, 154
Meijer CJLM, 438, 504
Mengoli C, 292
Mertz KJ, 201
Miller JN, 551
Miller WC, 530
Mills J, 270
Mills S, 320
Minchang W, 480
Minkoff H, 338
Miranda AE, 491

Mognomi RC, 201
Molitor F, 393, 539
Moncada J, 249
Monini P, 159
Moore SG, 530
Morency P, 458
Morré SA, 504
Morrow S, 393
Morse SA, 21
Moscicki AB, 296
Moseley KE, 188
Moses S, 465
Muth SQ, 644

N

Nakashima AK, 483
Ndinya-Achola J, 417
Ndulo J, 496
Neal SW, 46
Newman DR, 446
Newton EAC, 363
Niccolai LM, 284
Norpech J, 358
Nsuami M, 473

O

Oh MK, 175
Owen-O'Dowd J, 530

P

Pack RP, 175
Padian N, 393
Page-Shafer K, 393
Palamara G, 87
Paltiel AD, 610
Palù G, 292
Parolin C, 292
Paterson B, 133
Pépin J, 401, 458
Pequegnat W, 101, 127
Peralta L, 252, 313
Peterman TA, 446
Petros H, 284
Pettifor A, 371
Pezzotti P, 159
Phalla T, 320
Ping G, 143
Ping L, 480
Pintos J, 79
Postma MJ, 518
Potterat JJ, 60, 644
Poulin R, 558
Prignano G, 87
Privette A, 530
Project RESPECT Study Group, 446

Q

Qun C, 115

R

Rabe LK, 74
Radebe F, 21
Raghunathan P, 371
Ragsdale S, 236
Ralepeli S, 1
Rein DB, 32
Rezza G, 87, 159
Richardson H, 79
Riolo CS, 617
Robles RR, 119
Roegner R, 446
Rogers J, 446
Rogers WB, 168
Rotchford K, 243
Rothenberg R, 12, 350, 411
Rowniak S, 249
Ruiz JD, 393, 539

S

Saikku P, 425
Sarmati L, 159
Satcher D, 66
Schachter J, 127, 249, 456
Schillinger JA, 329
Schmid S, 21
Schmidt KA, 278
Schmitz JL, 530
Schneider H, 278
Schrader M, 12
Scioccati L, 292
Seage III GR, 119
Shahan J, 154
Shaw H, 249
Shengchun W, 115
Shi F, 480
Shih JW, 178
Silberstein GS, 508
Singer L, 508
Skov S, 358
Sobel JD, 230
Somsé P, 458
Sopheab H, 320
Spencer JN, 19
Spinola SM, 111
St. Louis ME, 53, 68, 201, 329, 411, 491
Steen R, 1
Stein Z, 431
Stoner BP, 146, 193, 215
Stover J, 572
Strum AW, 243
Suligoi B, 292
Supplement to HIV/AIDS Surveillance Study Group, 483
Suss AL, 289
Svare EI, 438

T

Tabrizi SN, 133, 358
Tambe P, 12, 68
Tao G, 32
Tchangmena OB, 159
Tellier P, 79
Temmerman M, 417
Thattassery E, 278
Thompson DA, 386
Tishelman C, 496
Toma L, 159
Toomey K, 68
Trees DL, 46, 68
Tsai Y-K, 386
Tshabalala V, 21

V

Van Dam CJ, 9
van den Brule AJC, 438, 504
van den Hock A, 518
van Valkengoed IGM, 504
Vargas PM, 491
Viana MC, 468, 491
Vining-Bethea S, 119
Vivar A, 386
Voigt R, 508
Vuylsteke B, 1

W

Wada T, 93
Walboomers JMM, 438
Wald A, 266
Wallace J, 93
Walsh J, 371
Wasserheit JN, 311, 411
Wee S, 39, 208
Weiss JB, 21
Welner SL, 272
Welte R, 518
Wenling C, 480
Whittington WL, 193, 215
Wilkinson D, 243
Wilkins V, 371
Williams OC, 12
Wilson CM, 296
Wilson ML, 617
Witte SS, 93
Wong E, 539
Wong ML, 39, 208
Worm AM, 438

X

Xibao Z, 480

Y

Yeo AET, 178

Z

Zago A, 468
Zenilman J, 127, 252, 313, 446
Zenilman JM, 154, 224
Zhang G-C, 138
Zimet GD, 49

INDEX OF SUBJECTS

A

Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection
Adolescents
  chlamydia risk in, cervical ectopy and, 313
  cytomegalovirus infection in, 296
  hepatitis B in, 296
  hepatitis C in, 296
  inner-city, PID risk factors in, 289
  inner-city male, gonorrhea in, 201
African Americans
  adolescent, PID risk factors in, 289
  female, heterosexual transmission of hepatitis B/C and HIV and, 338
  HSV-2 infection in, prevalence and correlates of, 393
  inner-city male adolescent and young adult, gonorrhea in, 201
  young male incarcerated, asymptomatic STDs in, 175
AIDS. *See* Human immunodeficiency virus infection
Antibiotic prophylaxis, for syphilis, acceptability of, 188
Antibiotic resistance, of *N. gonorrhoeae*, 46, 115
  in China, 480
  *tet*M subtype and, 46

B

Bacterial vaginosis, diagnosis of, in Peruvian family planning/antenatal clinic, 386
Brazil, human herpesvirus 8 seroprevalence in, Kaposi sarcoma and, 468
Bridge populations
  interventions in, declining STD prevalence and, 1, 9 (editorial)
  male Cambodian, 320
  STD transmission via, 320, 327 (editorial)

C

Cambodia, male sexual bridging in, 320, 327 (editorial)
Candida vaginitis, self-reported incidence of, 230
Ceftriaxone, *N. gonorrhoeae* sensitivity to, in China, 480
Centers for Disease Control and Prevention (CDC), National Plan to Eliminate Syphilis from the U.S., 63, 66
Central African Republic, formal vs. informal sector treatment in, 458, 465 (editorial)
Cervical ectopy
  adolescent chlamydia risk and, 313
  histologic development of, 252
China
  antibiotic sensitivity of *N. gonorrhoeae* in, 480
  STD epidemiologic trends in, 138, 143 (editorial)
Chlamydial infection
  cervical ectopy and, in adolescents, 313
  diagnosis of, in Peruvian family planning/antenatal clinic, 386
  in female sex workers, clinical algorithms for, 401
  in gay men, 249
  hormonal contraception and, in adolescents, 313
  male, screening for, 588
  network analysis of, 215, 224 (editorial)
  recurrent, in core transmitters, 343, 350 (editorial)
  screening for
    cost-effectiveness of, 518
    criteria for, 165
      literature-derived, 504
    in males, 588
    school-based, participation in, 473
    urinary, 146
  untreated, duration of, 329
  vaginal wet mount and endocervical Gram stain for, clinical utility of, 530
Chlamydia trachomatis, patient-administered tampon specimens for, 133
Chlorhexidine, in vitro activity of, 74
Ciprofloxacin, *N. gonorrhoeae* resistance to, 115
Condoms
  availability of, in South Africa, 353
  slippage and breakage of, among sex workers, 208
  use of
    after hierarchy counseling, 93
    for oral sex, among Indonesian female sex workers, 39
Contact tracing. *See also* Partner notification
  in network analysis, 627
Core groups
  identification of, 343, 350 (editorial)
  interventions in, declining STD prevalence and, 1, 9 (editorial)
Cytomegalovirus infection, in adolescents, 296

D

Denmark, HPV infection in sex workers in, age-related decline in, 438
Depot-medroxyprogesterone acetate, adolescent chlamydia risk and, 313
Deterministic extended pair models, in mathematical modeling, 600
Developing countries. *See also specific countries*
  access to and quality of care in, 458, 465 (editorial)
  HIV policies and programs in, mathematical modeling and, 572
  type 2 HSV infection in, 21, 30 (editorial)
Disabled women, STDs in, 272
Drug abusers
  HTLV infection in, 87
  vaginal microbicide use by, 119
Drug peddlers, in Central African Republic, 458, 465 (editorial)
Drug resistance. *See* Antibiotic resistance
Drug sensitivity, of *N. gonorrhoeae*, in China, 480

E

Economic modeling, 610
Emergency department, STD management in, 154
Endocervical Gram stain, for gonorrhea and chlamydia, clinical utility of, 530
Extended pair models, in mathematical modeling, 600

F

Female condom use
  after hierarchy counseling, 431
  by sex workers, predictors of, 93
Female sex workers. *See* Sex workers
Foreign bodies, self-implantation of in penis, 152

G

Gay men
  chlamydial infection in, 249
  sex solicitation via Internet by, STD risks and, 545
Genital herpes. *See* Herpes simplex virus infection
Genital microflora, chlorhexidine effects on, 74
Genital ulcers. *See also* Herpes simplex virus infection
  HIV infection and, in South Africa, 21, 30 (editorial)
  U.S. health care expenditures for, 32
GERMS models, 617
Gonorrhea
  diagnosis of, in Peruvian family planning/antenatal clinic, 386
  in female sex workers, clinical algorithms for, 401
  in inner-city male adolescents and young adults, 201
  network analysis of, 215, 224 (editorial)
  opacity protein expression in, 278
  recurrent, in core transmitters, 343, 350 (editorial)
  screening criteria for, 165
  urine screening for, 146
  vaginal wet mount and endocervical Gram stain for, clinical utility of, 530
Gram stain, endocervical, for gonorrhea and chlamydia, clinical utility of, 530
Greece, STD patients in, HIV seroprevalence and risk factors in, 263

H

Haemophilus ducreyi, human model of experimental infection with, 111
Handicapped women, STDs in, 272
Health care expenditures, for genital herpes, 32
Hemophiliacs, hepatitis G virus prevalence in, 178
Hepatitis B

in adolescents, 296
heterosexual transmission of, in inner-city females, 338
prevalence of, in low-income young women, 539
Hepatitis C
in adolescents, 296
heterosexual transmission of, in inner-city females, 338
Hepatitis G virus, prevalence of, in hemophiliacs and their female sex partners, 178
Herpes simplex virus, type 2, POCkit HSV-2 Rapid Test for, 266, 270 (editorial)
Herpes simplex virus infection
HIV infection and, 21, 30 (editorial)
prevalence and correlates of, in low-income population, 393
seroprevalence of, in Italy, 292
transmission of, mathematical model of, 363
U.S. health care expenditures for, 32
Hierarchy counseling, condom use after, 431
Hispanics
adolescent, PID risk factors in, 289
female, heterosexual transmission of hepatitis B/C and HIV and, 338
HSV-2 infection in, prevalence and correlates of, 393
young male incarcerated, asymptomatic STDs in, 175
HIV reproduction number formula, 644
Homosexual men
chlamydial infection in, 249
sex solicitation via Internet by, STD risks and, 545
Hormonal contraception, adolescent chlamydial risk and, 313
Hormones, sex, cervical ectopy and, 252
Human herpesvirus 8 infection
distribution and transmission of, in Northern Cameroon, 159
Kaposi sarcoma and, in Brazil, 468
Human immunodeficiency virus, shedding of, in STD coinfection, 243
Human immunodeficiency virus infection
in adolescents, hepatitis B/C and cytomegalovirus infection in, 296
diagnosis of, in Peruvian family planning/antenatal clinic, 386
genital ulcers and, in South Africa, 21, 30 (editorial)
heterosexual transmission of
in inner-city females, 338
risk behaviors for, 483
prevention of
behavioral and biological outcome measures for, 101
NIHM/APPC Workgroup on Behavioral and Biological Outcomes in HIV/STD Prevention Studies for, 127
seroprevalence and risk factors for, in STD patients, 259
surveillance programs for, 60 (letter)
in syphilis patients, 53
T. vaginalis reinfection in, 284
transmission of, effects of STD treatment on, 411
Human papillomavirus infection
cervical, oncogenic risk determinants for, 79
in sex workers, age-related decline in, 438
Human T-lymphotropic virus infection, risk factors for, 87

I

Immunization, for STDs, 49
Incarcerated/detained persons
female Brazilian, STD prevalence and risk factors in, 491
syphilis screening and treatment program for, 508
young male minority, asymptomatic STDs in, 175
Informal sector treatment
in Central African Republic, 458, 465 (editorial)
in Zambia, 496
Injection drug users
HTLV infection in, 87
vaginal microbicide use by, 119
Internet, sex solicitation via, STD risks and, 545
Intravaginal substances, STD transmission and, 183
Italy, HSV-2 seroprevalence in, 292

J

Jail-based screening and treatment program, for syphilis, 508

K

Kaposi sarcoma, human herpesvirus 8 seroprevalence and, in Brazil, 468
Kenya, STD prevalence and risk factors in STD clinics in, 417

L

Latinos. *See* Hispanics

M

Mathematical modeling, 627, 636. *See also* Network analysis
deterministic extended pair models in, 600
economic modeling and, 610
GERMS models in, 617
of HIV infection and AIDS, policy implications of, 572
HIV reproduction number formula in, 644
of HSV-2 transmission, 363
in network analysis, 558
utility of, 556
Measured behavior, STD risk and, 446, 452 & 456 (editorials)
Mexican Americans. *See* Hispanics
Microflora, genital, chlorhexidine effects on, 74
Moment closure, in network analysis, 600
Mycoplasma genitalium, in nongonococcal urethritis, 226

N

National Institutes of Health, NIHM/APPC Workgroup on Behavioral and Biological Outcomes in HIV/STD Prevention Studies, 127
National Plan to Eliminate Syphilis from the U.S. (CDC), 63, 66
Neisseria gonorrhoeae
antibiotic resistance of, 115
in China, 480
chlorhexidine effects on, 74
patient-administered tampon specimens for, 133
tetracycline-resistant, prevalence and *tet*M subtype of, 46
urine screening for, 146
Neisseria gonorrhoeae MS11 mkC opacity proteins, 278
Network analysis. *See also* Mathematical modeling
core group identification and, 343, 350 (editorial)
deterministic extended pair models in, 600
of gonococcal and chlamydial infections, 215, 224 (editorial)
HIV reproduction number formula in, 644
local vs. global centrality measures in, 579
methodologies in, 558, 627
partner duration in, 627
sexual mixing patterns in, 558
of STD acquisition/transmission risks, 579
in syphilis control, 12, 19 (editorial)
Nodules, artificial penile, 152
Nongonococcal urethritis
Mycoplasma genitalium in, 226
trichomonal, 236, 241 (editorial)

O

Oral contraceptives, adolescent chlamydia risk and, 313
Oral sex, condom use for, among Indonesian female sex workers, 39
Outcome measures, for HIV prevention interventions, 101

P

Pair models, in mathematical modeling, 600
Partner duration, in network analysis, 627
Partner notification
patient perspectives on, 193
vs. social network analysis, 343, 350 (editorial)
for syphilis, social network methods for, 12, 19 (editorial)
Pelvic inflammatory disease, in inner-city adolescents, risk factors for, 289
Penis, artificial nodules of, 152
Peru, family/antenatal clinics in, STD diagnosis and management in, 386
Pharmacies, STD treatment in, in Central African Republic, 458, 465 (editorial)
pH testing, vaginal, in screening, 386
POCkit HSV-2 Rapid Test, premarket evaluation of, 266, 270 (editorial)
Poverty. *See* Socioeconomic status
Prisoners. *See* Incarcerated/detained persons

Project RESPECT, measured behavior and STD risk in, 446, 452 & 456 (editorials)
Prostitutes. *See* Sex workers

Q

Quality of care, in developing countries, 458, 465 (editorial)

R

Reproduction number formula, 644
Reproductive hormones, cervical ectopy and, 252

S

School-based screening, participation in, 473
Screening
  for chlamydial infection
    cost-effectiveness of, 518
    criteria for, 165
      literature-derived, 504
    literature-derived criteria for, 504
    in males, 588
    school-based, participation in, 473
    urinary, 146
  clinical utility of, 588
  in family planning/antenatal clinic, in Peru, 386
  in incarcerated minority male youth, 175
  school-based, participation in, 473
  for syphilis, acceptability of, 188
  urine, for *N. gonorrhoeae* and *C. trachomatis*, 146
Sex hormones, cervical ectopy and, 252
Sex-partner networks. *See also* Network analysis
  gonococcal and chlamydial, comparative epidemiology of, 215, 224 (editorial)
Sex solicitation, via Internet, STD risks and, 545
Sexual behavior
  heterosexual transmission of hepatitis B/C, and HIV and, 338
  HTLV infection and, 87
  Internet sex solicitation, STD risks and, 545
  measured, STD risk and, 446, 452 & 456 (editorials)
Sexual bridging
  by Cambodian men, 320
  interventions for, declining STD prevalence and, 1, 9 (editorial)
  STD transmission via, 320, 327 (editorial)
Sexually transmitted disease clinics
  patient attitudes toward, 188
  STD prevalence and risk factors in, in Kenya, 417
Sexually transmitted diseases
  ambulatory management of, in inner-city emergency department, 154
  asymptomatic, in incarcerated minority male youth, 175
  declining prevalence of, after core-group intervention, 1, 9 (editorial)
  diagnosis of, in Peruvian family planning/antenatal clinic, 386
  in disabled women, 272
  epidemiologic trends in, in China, 138, 143 (editorial)
  HIV seroprevalence and risk factors in, 259
  HIV shedding in, 243
  multiple, seropositivity to, 425
  prevention of
    four-component intervention for, 9 (editorial)
    NIHM/APPC Workgroup on Behavioral and Biological Outcomes in HIV/STD Prevention Studies for, 127
  risk of, measured behavior and, 446, 452 & 456 (editorials)
  syndromic management of, 371
  treatment of in formal vs. informal sectors, in Central African Republic, 458, 465 (editorial)
  vaccines for, 49
Sexually Transmitted Diseases, a retrospective, 554
Sexual mixing patterns, estimation of, 558
Sex workers
  clinical algorithms for STDs in, 401
  condom slippage and breakage among, 208
  condom use for oral sex by, 39
  female condom use by, predictors of, 93
  HPV infection in, age-related decline in, 438
  STD prevalence in clients of, 358
Snowball sampling, in sexual mixing pattern estimation, 558
Social network analysis. *See* Network analysis
Socioeconomic status
  adolescent PID risk factors and, 289
  asymptomatic STDs and, 175
  gonorrhea and, 201
  hepatitis B prevalence in young women and, 539
  heterosexual transmission of hepatitis B/C and HIV and, 338
  HSV-2 infection prevalence and correlates and, 393
South Africa
  condom availability in, 353
  declining STD prevalence in, after core-group intervention, 1, 9 (editorial)
  genital ulcer disease and HIV infection in, 21, 30 (editorial)
Spectinomycin, *N. gonorrhoeae* sensitivity to, in China, 480
Staining, endocervical, for gonorrhea and chlamydia, clinical utility of, 530
Sub-Saharan Africa. *See* Developing countries *and specific countries*
Substance abuse
  HTLV infection and, 87
  vaginal microbicide use and, 119
Surveillance, for HIV infection, 60 (letter)
Syphilis
  antibiotic prophylaxis for, acceptability of, 188
  in Atlanta, case-control study of, 68
  CDC eradication program for, 63, 66
  as community health barometer, 305, 311 (editorial)
  control of, social network methods for, 12, 19 (editorial)
  diagnosis of, in Peruvian family planning/antenatal clinic, 386
  epidemic, in Nashville, TN 1996–1998, 168
  HIV prevalence in, 53
  jail-based screening and treatment program for, 508
  prevention of, 305, 311 (editorial)
  screening for, acceptability of, 188

T

Tampon specimens, patient-administered, for *C. trachomatis* and *N. gonorrhoeae*, 133
Tetracycline-resistant *N. gonorrhoeae*, prevalence and *tet*M subtype of, 46
Thailand, STD prevalence in sex worker clients in, 358
Traditional remedies, utilization of, in Zambia, 496
Transmission models. *See* Mathematical modeling; Network analysis
Trichomonas vaginalis, chlorhexidine effects on, 74
Trichomonas vaginalis infection
  diagnosis of, in Peruvian family planning/antenatal clinic, 386
  in men, 236, 241 (editorial)
  recurrent, in HIV-infected women, 284
Turner, Thomas Bourne, tribute to, 551

U

Urine screening, for *N. gonorrhoeae* and *C. trachomatis*, 146

V

Vaccines, for STDs, 49
Vaginal candidiasis, self-reported incidence of, 230
Vaginal microbicides, use of by drug abusers, 119
Vaginal pH testing, in screening, 386
Vaginal wet mount, for gonorrhea and chlamydial infection, clinical utility of, 530

W

Whiff test, in screening, 386

Z

Zambia, use of professional vs. traditional remedies in, 496